investorAi Investment driven Artificial Intelligence^TM

We are proud to announce that as of 13th June 2024 we are a Private Client facility. All subscribers were migrated, free of charge, to our Private Client services so we could concentrate on you personally, rather than focus on a subscriber model.

After speaking to many of you personally you had told us you preferred this course of action, and so we listened!

Our duty of care is to you first and not to subscriber numbers. Our duty of care is to grow your wealth. Our AI engine (Aeryn) has had some phenomenal success over this past year and we'd like to continue that but feel it is only really possible if we concentrate on building the AI around each of our treasured clients.

Aeryn can read and understand the news and has done for several years now. What we may miss as humans is something Aeryn does not do. So when 'she' starts to pick up on more large banks and more news articles betting on bonds then the reports get flagged to us and to our treasured Private Clients.

We already wrote advice on the bond trade last week and have taken the company's private portfolio in this direction as well. But, Aeryn suggests the bond trade is anticipated to dominate the remainder of 2024, and is gaining traction ahead of a crucial inflation report, which will be pivotal for its success (based on Citi and JPMorgan trades). The trade; predicting the US yield curve will steepen, is gaining momentum.

The upcoming consumer price index (CPI) release on Thursday 11th July 2024 will be closely watched for further validati ...

Read more

Bitcoin prices rebounded on July 5, 2024, recovering after hitting a four-month low amidst weak market conditions. The price also continues an upward trajectory today (8th July 2024). Included in this article is a chart from Aeryn (AI engine) which traders and investors will likely find useful and our analysis as to where the price may next head.

In this client only article:

Bitcoin has risen this morning of 8th July 2024 to over $57,000. This marks a gain of over 5.8% from its low of $53,717.34, reached shortly after midnight EST, the lowest since late February 2024.

Despite some volatility after peaking above $56,800, the cryptocurrency maintained most of its gains from last week and has tentatively continued th ...

Read more

Investors funneled $19 billion into bond funds in the week leading up to Wednesday 3rd July 2024, marking the largest inflow since February 2021 as they sought to lock in high yields, according to a Bank of America (BofA) research note released today (5th July 2024). Cash funds also saw significant activity, with $51.9 billion in inflows, the largest in two months, based on data from EPFR, as reported by BofA.

The surge in yields on fixed income assets, driven by central banks raising interest rates to combat inflation, has attracted investors to bonds and money market funds. BofA analysts noted that investors are "locking in 'peak yields'" in anticipation of potential rate cuts later this year (something we also advised clients in ...

Read more

The US labor market added more jobs than expected in June, while the unemployment rate unexpectedly rose, reaching its highest level since November 2021, indicating a continued cooling in the job market.

Data from the Bureau of Labor Statistics (BLS) released on Friday showed that the US economy added 206,000 nonfarm payroll jobs in June, surpassing the 190,000 expected by economists.

The unemployment rate increased to 4.1%, up from 4% the previous month, marking the highest reading in nearly three years. June's job additions were slightly lower than May's, with revised figures showing 218,000 jobs added in May, down from the initially reported 272,000.

Following the report, stock futures turned higher, adding to ...

Read more

GSK (GSK.L) has been an extremely good investment for us. Aeryn (the AI engine) has made good predictions and a good and healthy dividend yield has seen us get some great profits for our clients. The news that GSK has acquired the full rights to develop, manufacture, and market COVID-19 and influenza vaccines from Germany's CureVac is some further good news.

GSK, the UK’s second-largest pharmaceutical company, is paying €400 million (£339 million, $430 million) upfront, with the potential for an additional €1.05 billion to the biotech firm CureVac. The two companies have restructured their existing collaboration ...

Read more